Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tjulandin, S. A.
Right arrow Articles by Garin, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tjulandin, S. A.
Right arrow Articles by Garin, A. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 2:667-672, 1991
© 1991 European Society for Medical Oncology

research-article

Original article: VAB-6 and cisplatin-cyclophosphamide combinations in the treatment of metastatic seminoma patients: The U.S.S.R. experience

S. A. Tjulandin1, A. V. Khlebnov1, R. J. Nasirova1, Z. P. Mikhina2, G. V. Molchanov3, V. N. Sholokhov3, V. A. Sokolov4, N. A. Vetrova3 and A. M. Garin1

1Clinical Pharmacology Department, The All-Union Cancer Research Center AMS of the U.S.S.R. Moscow, U.S.S.R.
2Radiology Department, The All-Union Cancer Research Center AMS of the U.S.S.R. Moscow, U.S.S.R.
3Tumor Diagnostic Division, The All-Union Cancer Research Center AMS of the U.S.S.R. Moscow, U.S.S.R.
4Clinical Radioimmunology Laboratory, The All-Union Cancer Research Center AMS of the U.S.S.R. Moscow, U.S.S.R.

Correspondence to: S. A. Tjulandin, M.D., Clinical Pharmacology Department, All-Union Cancer Research Center AMS of the US.S.R., 24 Kashirskoesh., Moscow, 115478, US.S.R.

In a non-domized study the treatment results of 59 patients with disseminated seminoma were evaluated: 21 patients were treated with a VAB-6 combination and 38 with a CP (cyclophosphamide and cis-platin) combination. After VAB-6 CR was observed in 8 patients and 6 achieved CR with additional treatment: 1 with chemotherapy (PVB) and 5 with radiotherapy (RT). The final CR rate was 67%. At a median follow-up of 38 (11-70) months 15 (71%) are alive, and 11 of them (52%) are NED; 6 have died. Of the 38 patients treated with CP alone only 18 achieved CR and 9 had a CR after additional RT and 1 chemotherapy (VAB-6), the overall CR rate was 72%. The median follow-up is 24 (4-55) months, 28 (74%) are alive, 24 (66%) are currently NED, and 9 have died. Both regimens were well tolerated, the main toxicity being leukopenia: 48% (WHO grade lll-lV-5%) for VAB-6, and 59% (13%) for CR Hearing loss was registered in 8 patients receiving CP and in 2 receiving VAB-6. There were no fatal toxicities. Thus, VAB-6 and CP regimens seem to have compatible and high activity in disseminated seminoma.

advanced seminoma, chemotherapy, radiotherapy, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
R. J. Amato, R. Millikan, D. Daliani, L. Wood, C. Logothetis, and A. Pollack
Cyclophosphamide and Carboplatin and Selective Consolidation in Advanced Seminoma
Clin. Cancer Res., January 1, 2000; 6(1): 72 - 77.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.